260 related articles for article (PubMed ID: 32023846)
1. Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment.
Palombo R; Verdile V; Paronetto MP
Cells; 2020 Jan; 9(2):. PubMed ID: 32023846
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9.
Fidaleo M; Svetoni F; Volpe E; Miñana B; Caporossi D; Paronetto MP
Oncotarget; 2015 Oct; 6(31):31740-57. PubMed ID: 26450900
[TBL] [Abstract][Full Text] [Related]
3. The Promoter-Associated Noncoding RNA
Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
[TBL] [Abstract][Full Text] [Related]
4. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
[TBL] [Abstract][Full Text] [Related]
6. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
7. The DNA/RNA helicase DHX9 orchestrates the KDM2B-mediated transcriptional regulation of YAP1 in Ewing sarcoma.
Chellini L; Scarfò M; Bonvissuto D; Sette C; Paronetto MP
Oncogene; 2024 Jan; 43(4):225-234. PubMed ID: 38017132
[TBL] [Abstract][Full Text] [Related]
8. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
9. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein.
Paronetto MP; Bernardis I; Volpe E; Bechara E; Sebestyén E; Eyras E; Valcárcel J
Cell Rep; 2014 May; 7(4):1211-26. PubMed ID: 24813895
[TBL] [Abstract][Full Text] [Related]
10. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
13. hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.
Passacantilli I; Frisone P; De Paola E; Fidaleo M; Paronetto MP
Nucleic Acids Res; 2017 Dec; 45(21):12270-12284. PubMed ID: 29036465
[TBL] [Abstract][Full Text] [Related]
14. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
15. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract][Full Text] [Related]
16. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
17. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
19. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene.
Bertrand JR; Pioche-Durieu C; Ayala J; Petit T; Girard HA; Malvy CP; Le Cam E; Treussart F; Arnault JC
Biomaterials; 2015 Mar; 45():93-8. PubMed ID: 25662499
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
